Oncology

Novarad and Ikonopedia Partner to Elevate Women’s Health in One Complete Mammography Platform

Medical software provider Novarad has formed a strategic partnership with Ikonopedia, a structured breast reporting and MQSA management system designed to improve reporting efficiency and optimize facility operations. Ikonopedia’s next-generation breast reporting and tracking system for mammography will integrate with Novarad’s NovaMG PRO mammography platform. By combining leading-edge technologies with innovative software applications to connect patient care, Novarad’s complete care platform can…

Bia Care Partners with GenesisCare to Support Women Experiencing Menopause as a Side Effect of Cancer Treatment

Around 30% of women treated for breast cancer will experience the sudden onset of menopause symptoms, as a result of their treatment. Over 200,000 women every year in England will experience this side effect during their cancer care, with no treatment currently offered as standard. If women do not receive support, a quarter will leave employment as a result of their menopause…

Israeli Femtech Company MobileODT Participates In India’s Largest Cervical Cancer Screening Program

MobileODT, an Israeli femtech company innovating in cervical cancer screening, is supporting a national cervical cancer screening project in India. This will be the most comprehensive and largest cervical cancer screening program performed in India, to date. The project will be run by Karkinos Healthcare in strategic collaboration with GenWorks Health, MobileODT’s exclusive distributor in India. The partnership will adopt the World Health Organization’s (WHO) recommended Human Papilloma Virus (HPV)…

New Survey: Women Are Skipping Cancer Screenings During the Pandemic, But Plan to get ‘Back on the Books’

The Prevent Cancer Foundation has released the results of a survey conducted with 2000+ women and people assigned female at birth in the U.S, that shows that women are skipping cancer screenings during the pandemic. 90% of women say when local pandemic restrictions were lifted, they engaged in normal activities, such as visiting family and friends, dining out and shopping, but only 48%…

Fujifilm and ScreenPoint Medical Now Offer Providers an AI Solution Designed for Early Breast Cancer Detection

FUJIFILM, a provider of diagnostic imaging and medical informatics solutions, has announced that its ASPIRE Cristalle mammography system with digital breast tomosynthesis (DBT) now offers ScreenPoint Medical’s new, FDA cleared Transpara powered by Fusion AI for 2D and 3D mammography in the United States. ScreenPoint Medical’s AI solution, coupled with the ASPIRE Cristalle mammography system, displays breast screening findings at a doctor’s reading workstation or PACS…

AOA Dx Secures a Suite of IP Related To Early Detection in Support of its Mission to Transform Ovarian Cancer Diagnostics

AOA Dx has signed an Exclusive License Agreement with Professor H. Uri Saragovi, a Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University, to secure a suite of IP related to utilizing gangliosides for early cancer detection through liquid biopsies. A family of gangliosides function as tumor markers, as they are low or absent…

Women’s Health Startup Mammogen Announces a $2M Seed Round and the Debut of its genTRU Liquid Biopsy Platform

Women’s health startup Mammogen has announced the closing of its $2M seed round. The round was oversubscribed by a diverse group of high-net-worth investors, comprising 52% women, members of the LGBTQ+ community, and veterans from the US Armed Forces, according to the company.  “The vast diversity across our investor base is evidence that the world is ready for a truly differentiated women’s health narrative,”…

AOA Dx Raises a $2.5 Million Seed Round to Develop the First Non-invasive Ovarian Cancer Liquid Biopsy Diagnostic Test 

AOA Dx earlier today announced that they have been accepted to Y Combinator’s 2021 summer cohort and have closed a $2.5 million seed round to develop AKRIVIS GD, a liquid biopsy test that is set to revolutionize the future of ovarian cancer diagnostics.  AOA Dx has been working in close collaboration with world renowned cancer researcher Professor H. Uri Saragovi, Senior Investigator…